 Martin McCarter
Concepts (792)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 50 | 2024 | 760 | 7.700 |
Why?
| | Esophageal Neoplasms | 29 | 2025 | 321 | 5.510 |
Why?
| | Skin Neoplasms | 34 | 2024 | 855 | 4.690 |
Why?
| | Adenocarcinoma | 29 | 2025 | 940 | 3.500 |
Why?
| | Esophagectomy | 20 | 2024 | 131 | 3.470 |
Why?
| | Sentinel Lymph Node Biopsy | 23 | 2022 | 115 | 2.670 |
Why?
| | Myeloid-Derived Suppressor Cells | 5 | 2024 | 66 | 2.500 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 38 | 2.210 |
Why?
| | Neoadjuvant Therapy | 15 | 2025 | 404 | 1.790 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 45 | 1.700 |
Why?
| | Rectal Neoplasms | 8 | 2024 | 149 | 1.690 |
Why?
| | Dendritic Cells | 13 | 2019 | 483 | 1.650 |
Why?
| | Pancreatic Neoplasms | 15 | 2024 | 938 | 1.640 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 385 | 1.630 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 1079 | 1.550 |
Why?
| | Stomach Neoplasms | 6 | 2025 | 122 | 1.470 |
Why?
| | Lymphatic Metastasis | 20 | 2023 | 352 | 1.350 |
Why?
| | Neoplasm Staging | 33 | 2025 | 1389 | 1.330 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1692 | 1.240 |
Why?
| | Tumor Escape | 4 | 2017 | 42 | 1.220 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 116 | 1.130 |
Why?
| | Colonic Neoplasms | 7 | 2024 | 258 | 1.110 |
Why?
| | Lymph Nodes | 15 | 2023 | 491 | 1.100 |
Why?
| | Humans | 209 | 2025 | 137585 | 1.100 |
Why?
| | Middle Aged | 103 | 2025 | 33479 | 1.080 |
Why?
| | Anus Neoplasms | 3 | 2024 | 33 | 1.070 |
Why?
| | Aged | 87 | 2025 | 23961 | 1.060 |
Why?
| | Neoplasms | 13 | 2025 | 2671 | 1.030 |
Why?
| | Peritoneal Neoplasms | 4 | 2024 | 93 | 1.030 |
Why?
| | Retrospective Studies | 56 | 2025 | 15657 | 1.010 |
Why?
| | Hyperglycemia | 3 | 2020 | 347 | 1.010 |
Why?
| | Intestinal Neoplasms | 2 | 2024 | 29 | 0.990 |
Why?
| | Cytoreduction Surgical Procedures | 5 | 2024 | 63 | 0.980 |
Why?
| | HIV-1 | 16 | 2022 | 864 | 0.960 |
Why?
| | Postoperative Complications | 20 | 2024 | 2654 | 0.940 |
Why?
| | Laparoscopy | 8 | 2024 | 466 | 0.920 |
Why?
| | HIV Infections | 20 | 2022 | 2836 | 0.910 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2021 | 1091 | 0.910 |
Why?
| | Intestine, Small | 2 | 2024 | 156 | 0.890 |
Why?
| | Survival Rate | 23 | 2025 | 1972 | 0.890 |
Why?
| | Sarcoma | 6 | 2025 | 188 | 0.890 |
Why?
| | Male | 116 | 2025 | 67762 | 0.850 |
Why?
| | Prognosis | 27 | 2024 | 4030 | 0.850 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 623 | 0.850 |
Why?
| | Female | 127 | 2025 | 73304 | 0.840 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 37 | 0.840 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 164 | 0.770 |
Why?
| | Lymph Node Excision | 8 | 2022 | 171 | 0.770 |
Why?
| | Tretinoin | 3 | 2023 | 123 | 0.770 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 118 | 0.740 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1142 | 0.720 |
Why?
| | T-Lymphocytes | 8 | 2024 | 1996 | 0.720 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 11 | 0.700 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 67 | 0.690 |
Why?
| | Radiosurgery | 4 | 2020 | 344 | 0.690 |
Why?
| | Anastomotic Leak | 4 | 2024 | 41 | 0.670 |
Why?
| | Colorectal Neoplasms | 6 | 2024 | 806 | 0.660 |
Why?
| | Survival Analysis | 16 | 2022 | 1325 | 0.660 |
Why?
| | Splenectomy | 1 | 2020 | 62 | 0.640 |
Why?
| | Chemoradiotherapy | 6 | 2024 | 225 | 0.640 |
Why?
| | Adult | 65 | 2024 | 37929 | 0.630 |
Why?
| | Ipilimumab | 2 | 2019 | 33 | 0.630 |
Why?
| | Piperazines | 5 | 2014 | 350 | 0.630 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 60 | 0.620 |
Why?
| | Ischemic Preconditioning | 3 | 2024 | 41 | 0.610 |
Why?
| | Myeloid Cells | 3 | 2020 | 148 | 0.610 |
Why?
| | Spleen | 6 | 2017 | 514 | 0.610 |
Why?
| | Granulocytes | 2 | 2017 | 80 | 0.590 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 142 | 0.590 |
Why?
| | Pyrimidines | 5 | 2014 | 470 | 0.580 |
Why?
| | Gastrointestinal Microbiome | 8 | 2021 | 697 | 0.570 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 76 | 0.570 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 558 | 0.570 |
Why?
| | Monocytes | 2 | 2020 | 563 | 0.560 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 27 | 0.560 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2129 | 0.550 |
Why?
| | Aged, 80 and over | 28 | 2024 | 7635 | 0.550 |
Why?
| | Time-to-Treatment | 4 | 2025 | 205 | 0.540 |
Why?
| | Combined Modality Therapy | 15 | 2024 | 1236 | 0.540 |
Why?
| | Pylorus | 1 | 2017 | 18 | 0.530 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.530 |
Why?
| | Mucous Membrane | 5 | 2024 | 125 | 0.520 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 900 | 0.520 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 35 | 0.500 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 115 | 0.500 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.500 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 45 | 0.500 |
Why?
| | Follow-Up Studies | 19 | 2024 | 5131 | 0.500 |
Why?
| | Leucovorin | 2 | 2019 | 81 | 0.490 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 606 | 0.480 |
Why?
| | Liver Neoplasms | 6 | 2024 | 786 | 0.480 |
Why?
| | Treatment Outcome | 27 | 2024 | 10811 | 0.460 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 210 | 0.440 |
Why?
| | Vitamin B Complex | 1 | 2014 | 44 | 0.440 |
Why?
| | Pancreatectomy | 5 | 2024 | 253 | 0.440 |
Why?
| | Salvage Therapy | 2 | 2014 | 142 | 0.430 |
Why?
| | Immune Tolerance | 4 | 2016 | 363 | 0.430 |
Why?
| | Esophagogastric Junction | 4 | 2024 | 51 | 0.430 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 179 | 0.430 |
Why?
| | Pelvis | 1 | 2014 | 102 | 0.420 |
Why?
| | Lymphocytes | 3 | 2021 | 397 | 0.420 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 114 | 0.410 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.410 |
Why?
| | Mohs Surgery | 1 | 2013 | 27 | 0.410 |
Why?
| | Mutation | 9 | 2025 | 3958 | 0.400 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 137 | 0.390 |
Why?
| | Biopsy | 3 | 2023 | 1129 | 0.380 |
Why?
| | Palliative Care | 1 | 2019 | 758 | 0.380 |
Why?
| | Microbiota | 5 | 2024 | 762 | 0.380 |
Why?
| | Anastomosis, Surgical | 3 | 2024 | 153 | 0.380 |
Why?
| | Hematologic Diseases | 1 | 2012 | 62 | 0.380 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.370 |
Why?
| | Prospective Studies | 21 | 2023 | 7604 | 0.370 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 56 | 0.370 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 683 | 0.370 |
Why?
| | Cytokines | 8 | 2021 | 2085 | 0.360 |
Why?
| | Up-Regulation | 4 | 2012 | 843 | 0.360 |
Why?
| | Dasatinib | 2 | 2024 | 54 | 0.360 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 307 | 0.350 |
Why?
| | Tumor Microenvironment | 6 | 2024 | 674 | 0.340 |
Why?
| | Thrombelastography | 2 | 2024 | 154 | 0.340 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 16 | 0.340 |
Why?
| | Granzymes | 2 | 2021 | 50 | 0.330 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 449 | 0.330 |
Why?
| | Homosexuality, Male | 3 | 2021 | 184 | 0.330 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 132 | 0.320 |
Why?
| | Benzamides | 5 | 2014 | 216 | 0.320 |
Why?
| | Databases, Factual | 7 | 2025 | 1357 | 0.320 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 30 | 0.320 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2021 | 25 | 0.320 |
Why?
| | Wounds and Injuries | 4 | 2009 | 758 | 0.310 |
Why?
| | Interferon-gamma | 6 | 2019 | 789 | 0.310 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 10 | 0.310 |
Why?
| | Medical Oncology | 4 | 2022 | 289 | 0.310 |
Why?
| | Immunotherapy | 5 | 2024 | 641 | 0.310 |
Why?
| | Young Adult | 19 | 2024 | 13209 | 0.300 |
Why?
| | Barrett Esophagus | 3 | 2020 | 149 | 0.300 |
Why?
| | Butyrates | 2 | 2021 | 61 | 0.300 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 500 | 0.300 |
Why?
| | Interleukin-15 | 2 | 2021 | 98 | 0.290 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 97 | 0.290 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 389 | 0.290 |
Why?
| | Cell Differentiation | 5 | 2016 | 1991 | 0.290 |
Why?
| | Blood Preservation | 2 | 2009 | 285 | 0.290 |
Why?
| | Disease-Free Survival | 8 | 2019 | 686 | 0.280 |
Why?
| | Inflammation Mediators | 2 | 2018 | 513 | 0.280 |
Why?
| | General Surgery | 2 | 2007 | 173 | 0.280 |
Why?
| | Nomograms | 2 | 2019 | 54 | 0.270 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.270 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 319 | 0.270 |
Why?
| | Colon | 3 | 2021 | 282 | 0.260 |
Why?
| | Dysbiosis | 3 | 2021 | 181 | 0.260 |
Why?
| | Immunocompromised Host | 1 | 2008 | 202 | 0.260 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 1043 | 0.260 |
Why?
| | Cells, Cultured | 9 | 2021 | 4193 | 0.260 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 194 | 0.260 |
Why?
| | Time Factors | 12 | 2024 | 6828 | 0.260 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 2 | 0.250 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 191 | 0.250 |
Why?
| | Lymphangioma | 1 | 2006 | 7 | 0.250 |
Why?
| | Th2 Cells | 2 | 2005 | 176 | 0.250 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 26 | 0.250 |
Why?
| | Population Surveillance | 2 | 2021 | 482 | 0.250 |
Why?
| | Transplantation Immunology | 1 | 2005 | 34 | 0.240 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 385 | 0.240 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 94 | 0.240 |
Why?
| | Mice | 24 | 2024 | 17787 | 0.240 |
Why?
| | Mice, Inbred BALB C | 6 | 2024 | 1272 | 0.240 |
Why?
| | Exome | 2 | 2017 | 231 | 0.240 |
Why?
| | Immunity, Innate | 4 | 2021 | 828 | 0.240 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 658 | 0.240 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 10 | 0.240 |
Why?
| | Catheter Ablation | 4 | 2016 | 350 | 0.240 |
Why?
| | Mentors | 1 | 2007 | 202 | 0.240 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 116 | 0.230 |
Why?
| | Computational Biology | 3 | 2025 | 644 | 0.230 |
Why?
| | Gastrectomy | 3 | 2025 | 126 | 0.230 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 289 | 0.230 |
Why?
| | Interleukin-10 | 3 | 2016 | 302 | 0.230 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 17 | 0.230 |
Why?
| | B-Lymphocytes | 3 | 2017 | 847 | 0.230 |
Why?
| | Hepatectomy | 3 | 2024 | 251 | 0.230 |
Why?
| | Radiation Injuries | 2 | 2021 | 145 | 0.230 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 110 | 0.230 |
Why?
| | Tumor Hypoxia | 1 | 2024 | 7 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 34 | 0.230 |
Why?
| | Virus Replication | 5 | 2017 | 483 | 0.220 |
Why?
| | Metastasectomy | 1 | 2024 | 20 | 0.220 |
Why?
| | Th1 Cells | 2 | 2019 | 143 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2005 | 201 | 0.220 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 217 | 0.220 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 27 | 0.220 |
Why?
| | Cohort Studies | 7 | 2025 | 5742 | 0.220 |
Why?
| | Signal Transduction | 9 | 2023 | 5079 | 0.210 |
Why?
| | Mice, Nude | 2 | 2024 | 698 | 0.210 |
Why?
| | Lymphocyte Count | 5 | 2017 | 148 | 0.210 |
Why?
| | Interferon-alpha | 3 | 2015 | 198 | 0.210 |
Why?
| | Ruminococcus | 2 | 2021 | 9 | 0.210 |
Why?
| | Carcinoma | 2 | 2006 | 240 | 0.210 |
Why?
| | Erythrocytes | 1 | 2009 | 700 | 0.210 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1092 | 0.210 |
Why?
| | Flow Cytometry | 6 | 2017 | 1178 | 0.210 |
Why?
| | Esophageal Stenosis | 1 | 2024 | 54 | 0.210 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 4 | 0.210 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 40 | 0.210 |
Why?
| | Adolescent | 15 | 2019 | 21513 | 0.200 |
Why?
| | Feces | 4 | 2021 | 484 | 0.200 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 220 | 0.200 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 486 | 0.200 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 75 | 0.200 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 10 | 0.200 |
Why?
| | Specialties, Surgical | 1 | 2023 | 75 | 0.200 |
Why?
| | Lysophospholipids | 1 | 2023 | 80 | 0.200 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 6 | 0.200 |
Why?
| | Intestines | 2 | 2017 | 357 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 98 | 0.200 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 480 | 0.200 |
Why?
| | Cell Count | 2 | 2017 | 324 | 0.190 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 183 | 0.190 |
Why?
| | Preoperative Care | 3 | 2018 | 362 | 0.190 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 13 | 0.190 |
Why?
| | Animals | 27 | 2024 | 36940 | 0.190 |
Why?
| | Ampulla of Vater | 2 | 2024 | 42 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 27 | 0.190 |
Why?
| | Patient Selection | 3 | 2014 | 696 | 0.190 |
Why?
| | Cryosurgery | 2 | 2019 | 59 | 0.190 |
Why?
| | HIV Seropositivity | 1 | 2022 | 125 | 0.190 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 79 | 0.190 |
Why?
| | Bacteria | 3 | 2018 | 858 | 0.190 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2691 | 0.190 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1276 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 39 | 0.180 |
Why?
| | Esophagoscopy | 2 | 2020 | 209 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 156 | 0.180 |
Why?
| | Critical Pathways | 1 | 2022 | 96 | 0.180 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 173 | 0.180 |
Why?
| | Carcinoma in Situ | 1 | 2001 | 49 | 0.180 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.180 |
Why?
| | Disease Progression | 2 | 2022 | 2757 | 0.180 |
Why?
| | Glucose | 3 | 2020 | 1020 | 0.180 |
Why?
| | Social Determinants of Health | 1 | 2025 | 267 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| | Firmicutes | 1 | 2021 | 19 | 0.170 |
Why?
| | Carcinoma, Lobular | 1 | 2001 | 49 | 0.170 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.170 |
Why?
| | Transcriptome | 2 | 2025 | 971 | 0.170 |
Why?
| | Risk Factors | 12 | 2024 | 10388 | 0.170 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2001 | 83 | 0.170 |
Why?
| | Diarrhea | 3 | 2008 | 184 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 916 | 0.170 |
Why?
| | Interleukin-2 | 5 | 2022 | 455 | 0.170 |
Why?
| | Bacterial Translocation | 2 | 2019 | 43 | 0.170 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 9 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 80 | 0.170 |
Why?
| | Receptors, CCR | 1 | 2020 | 8 | 0.170 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 39 | 0.170 |
Why?
| | Software | 1 | 2025 | 665 | 0.170 |
Why?
| | Delivery of Health Care | 2 | 2021 | 951 | 0.160 |
Why?
| | Interleukins | 2 | 2019 | 250 | 0.160 |
Why?
| | Platelet Count | 1 | 2020 | 86 | 0.160 |
Why?
| | United States | 14 | 2025 | 14841 | 0.160 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 77 | 0.160 |
Why?
| | Guidelines as Topic | 2 | 2018 | 275 | 0.160 |
Why?
| | Basophils | 1 | 2020 | 73 | 0.160 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.160 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 210 | 0.160 |
Why?
| | Dacarbazine | 4 | 2012 | 98 | 0.160 |
Why?
| | Scalp | 1 | 2019 | 35 | 0.160 |
Why?
| | Cell Proliferation | 6 | 2021 | 2475 | 0.160 |
Why?
| | Patient Care Planning | 2 | 2016 | 157 | 0.160 |
Why?
| | Surgeons | 1 | 2023 | 297 | 0.160 |
Why?
| | Apoptosis | 5 | 2021 | 2553 | 0.160 |
Why?
| | Gastric Bypass | 1 | 2021 | 119 | 0.160 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 11 | 0.160 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 6 | 0.160 |
Why?
| | Germ-Free Life | 1 | 2019 | 34 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2019 | 20 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2020 | 329 | 0.150 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 44 | 0.150 |
Why?
| | CD4 Antigens | 2 | 2011 | 141 | 0.150 |
Why?
| | Decision Making | 2 | 2019 | 900 | 0.150 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 16 | 0.150 |
Why?
| | Haploinsufficiency | 1 | 2019 | 56 | 0.150 |
Why?
| | Mastocytosis | 1 | 2019 | 12 | 0.150 |
Why?
| | Nutritional Support | 1 | 2019 | 34 | 0.150 |
Why?
| | Stomach | 3 | 2024 | 110 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 209 | 0.150 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 48 | 0.150 |
Why?
| | Intestinal Perforation | 1 | 2019 | 46 | 0.150 |
Why?
| | Abdominal Neoplasms | 2 | 2010 | 39 | 0.150 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 228 | 0.150 |
Why?
| | Immunophenotyping | 2 | 2017 | 318 | 0.150 |
Why?
| | Cell Line, Tumor | 6 | 2024 | 3412 | 0.150 |
Why?
| | Postoperative Period | 1 | 2020 | 342 | 0.150 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 73 | 0.150 |
Why?
| | Breast Neoplasms | 2 | 2001 | 2253 | 0.150 |
Why?
| | Photochemotherapy | 1 | 2019 | 44 | 0.150 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 99 | 0.150 |
Why?
| | Skin Pigmentation | 1 | 2019 | 49 | 0.150 |
Why?
| | Dilatation | 1 | 2019 | 67 | 0.150 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 10 | 0.150 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 51 | 0.150 |
Why?
| | Survivors | 2 | 2015 | 493 | 0.150 |
Why?
| | Th17 Cells | 1 | 2019 | 108 | 0.150 |
Why?
| | Esophagus | 1 | 2020 | 255 | 0.150 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 321 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 552 | 0.140 |
Why?
| | Brachytherapy | 1 | 2019 | 121 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 172 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 25 | 0.140 |
Why?
| | Hospitals | 2 | 2021 | 691 | 0.140 |
Why?
| | HIV | 1 | 2019 | 234 | 0.140 |
Why?
| | Risk Assessment | 4 | 2024 | 3457 | 0.140 |
Why?
| | Down-Regulation | 1 | 2020 | 657 | 0.140 |
Why?
| | Viral Tropism | 1 | 2017 | 31 | 0.140 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 26 | 0.140 |
Why?
| | Cell Movement | 4 | 2022 | 967 | 0.140 |
Why?
| | Food, Formulated | 1 | 1997 | 14 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.140 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 316 | 0.140 |
Why?
| | Laser Therapy | 1 | 2019 | 130 | 0.130 |
Why?
| | Deglutition Disorders | 1 | 2019 | 143 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 30 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 92 | 0.130 |
Why?
| | Liver | 4 | 2016 | 1943 | 0.130 |
Why?
| | Enteral Nutrition | 2 | 2010 | 202 | 0.130 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 140 | 0.130 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 53 | 0.130 |
Why?
| | Gastric Emptying | 1 | 2017 | 38 | 0.130 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 228 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 628 | 0.130 |
Why?
| | Arginine | 1 | 1998 | 271 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 44 | 0.130 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 215 | 0.130 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 840 | 0.130 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 38 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 224 | 0.130 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Immunologic Memory | 2 | 2016 | 353 | 0.130 |
Why?
| | Nutritional Status | 1 | 2019 | 350 | 0.130 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 70 | 0.130 |
Why?
| | Bystander Effect | 1 | 2016 | 16 | 0.130 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 106 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 218 | 0.130 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 90 | 0.120 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2031 | 0.120 |
Why?
| | Perioperative Care | 1 | 2018 | 178 | 0.120 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 135 | 0.120 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 27 | 0.120 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 80 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 233 | 0.120 |
Why?
| | Germinal Center | 1 | 2016 | 58 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 417 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1477 | 0.120 |
Why?
| | Morbidity | 3 | 2023 | 324 | 0.120 |
Why?
| | Exons | 3 | 2019 | 355 | 0.120 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 56 | 0.120 |
Why?
| | Postoperative Care | 1 | 1997 | 261 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 852 | 0.120 |
Why?
| | Adenoma | 1 | 2017 | 230 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1242 | 0.110 |
Why?
| | Ileus | 1 | 2014 | 12 | 0.110 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 8 | 0.110 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 86 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 338 | 0.110 |
Why?
| | Viral Load | 5 | 2018 | 466 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 539 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4149 | 0.110 |
Why?
| | Vinblastine | 2 | 2012 | 71 | 0.110 |
Why?
| | Quality of Life | 3 | 2019 | 2892 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 872 | 0.110 |
Why?
| | Endosonography | 1 | 2016 | 156 | 0.110 |
Why?
| | Ethanol | 1 | 2019 | 608 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1164 | 0.110 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.110 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 955 | 0.110 |
Why?
| | Dietary Supplements | 1 | 1998 | 561 | 0.110 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 801 | 0.100 |
Why?
| | Fluorouracil | 2 | 2019 | 208 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 195 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2526 | 0.100 |
Why?
| | Colectomy | 3 | 2008 | 100 | 0.100 |
Why?
| | Tumor Burden | 4 | 2022 | 309 | 0.100 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 362 | 0.100 |
Why?
| | RNA, Viral | 3 | 2013 | 656 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1710 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 85 | 0.100 |
Why?
| | Registries | 1 | 2021 | 2035 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 496 | 0.100 |
Why?
| | Oligopeptides | 1 | 2014 | 271 | 0.100 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 77 | 0.100 |
Why?
| | HIV Antibodies | 1 | 2013 | 62 | 0.100 |
Why?
| | Sensitivity and Specificity | 4 | 2015 | 1946 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.100 |
Why?
| | Ablation Techniques | 1 | 2012 | 36 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2426 | 0.100 |
Why?
| | Cisplatin | 2 | 2012 | 320 | 0.100 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 530 | 0.100 |
Why?
| | Mice, Knockout | 4 | 2024 | 3015 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 29 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2016 | 911 | 0.090 |
Why?
| | Palatine Tonsil | 3 | 2017 | 48 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 160 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 140 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 100 | 0.090 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 179 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 111 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 38 | 0.090 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 20 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 549 | 0.090 |
Why?
| | Colonic Pouches | 1 | 2011 | 15 | 0.090 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 185 | 0.090 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1774 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 631 | 0.090 |
Why?
| | Macrophages | 2 | 2001 | 1547 | 0.090 |
Why?
| | Ligands | 2 | 2023 | 664 | 0.090 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1509 | 0.090 |
Why?
| | Extremities | 2 | 2022 | 131 | 0.090 |
Why?
| | Cell Separation | 2 | 2010 | 318 | 0.080 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 6 | 0.080 |
Why?
| | Endocytosis | 1 | 2011 | 172 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 182 | 0.080 |
Why?
| | Interleukin-23 | 1 | 2010 | 19 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 327 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 286 | 0.080 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 39 | 0.080 |
Why?
| | Heparin | 1 | 2012 | 261 | 0.080 |
Why?
| | Gastric Fistula | 1 | 2010 | 9 | 0.080 |
Why?
| | Antigens, CD | 2 | 2015 | 521 | 0.080 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 14 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 303 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 786 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 138 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5757 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 246 | 0.080 |
Why?
| | Antiviral Agents | 1 | 2015 | 744 | 0.080 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 136 | 0.080 |
Why?
| | Escherichia coli | 1 | 2014 | 815 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1483 | 0.080 |
Why?
| | Rosaniline Dyes | 3 | 2007 | 13 | 0.080 |
Why?
| | Double-Blind Method | 4 | 2014 | 1993 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2009 | 37 | 0.080 |
Why?
| | Genomics | 2 | 2025 | 795 | 0.080 |
Why?
| | Odds Ratio | 3 | 2019 | 1070 | 0.080 |
Why?
| | Immunoglobulins | 2 | 2023 | 171 | 0.080 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 70 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2009 | 65 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1081 | 0.070 |
Why?
| | Phenotype | 5 | 2019 | 3196 | 0.070 |
Why?
| | ROC Curve | 2 | 2024 | 554 | 0.070 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 26 | 0.070 |
Why?
| | Hyalin | 1 | 2008 | 6 | 0.070 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 9 | 0.070 |
Why?
| | Gastrostomy | 1 | 2010 | 117 | 0.070 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 153 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 399 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 3295 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 718 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 81 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2007 | 216 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 889 | 0.070 |
Why?
| | ras Proteins | 1 | 2009 | 153 | 0.070 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 136 | 0.070 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 80 | 0.070 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 399 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1396 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 249 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.070 |
Why?
| | Logistic Models | 4 | 2016 | 2074 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3556 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 81 | 0.070 |
Why?
| | Interleukin-1beta | 2 | 2019 | 372 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 570 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 179 | 0.070 |
Why?
| | Career Mobility | 1 | 2007 | 69 | 0.070 |
Why?
| | Length of Stay | 3 | 2019 | 1215 | 0.070 |
Why?
| | Anticoagulants | 1 | 2012 | 664 | 0.070 |
Why?
| | Phylogeny | 2 | 2024 | 904 | 0.070 |
Why?
| | alpha-Defensins | 1 | 2006 | 10 | 0.060 |
Why?
| | Interleukin-6 | 4 | 1999 | 778 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2019 | 337 | 0.060 |
Why?
| | Watchful Waiting | 2 | 2018 | 81 | 0.060 |
Why?
| | Critical Care | 1 | 2012 | 601 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2009 | 325 | 0.060 |
Why?
| | New York | 2 | 2023 | 126 | 0.060 |
Why?
| | Laparotomy | 1 | 2007 | 109 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 19 | 0.060 |
Why?
| | History, 20th Century | 1 | 2007 | 325 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1738 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1639 | 0.060 |
Why?
| | Collagen | 1 | 2008 | 452 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 50 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 119 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 434 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 886 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 268 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 648 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 794 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 56 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 37 | 0.060 |
Why?
| | Quality Control | 1 | 2025 | 172 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 165 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 409 | 0.060 |
Why?
| | Chromones | 1 | 2024 | 44 | 0.060 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 28 | 0.060 |
Why?
| | Obesity, Morbid | 1 | 2008 | 264 | 0.060 |
Why?
| | Faculty, Medical | 1 | 2007 | 283 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2001 | 915 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2005 | 2833 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 41 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1178 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 90 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 52 | 0.050 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 259 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 306 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 273 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 388 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 35 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 510 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 245 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 166 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 43 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 58 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 98 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 47 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 985 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 312 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 10 | 0.050 |
Why?
| | Hypoglycemia | 1 | 2007 | 445 | 0.050 |
Why?
| | Child | 4 | 2019 | 21935 | 0.050 |
Why?
| | Technetium | 1 | 2001 | 10 | 0.050 |
Why?
| | Corticosterone | 1 | 2003 | 236 | 0.050 |
Why?
| | Injections, Intradermal | 1 | 2001 | 13 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2003 | 135 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 81 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 250 | 0.050 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2001 | 6 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.050 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 118 | 0.050 |
Why?
| | NF-kappa B | 1 | 2005 | 691 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 40 | 0.040 |
Why?
| | Mediastinoscopy | 1 | 2021 | 5 | 0.040 |
Why?
| | Leptin | 1 | 2003 | 236 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 411 | 0.040 |
Why?
| | Veterans | 1 | 2013 | 1476 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2001 | 189 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 99 | 0.040 |
Why?
| | Precision Medicine | 2 | 2016 | 429 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 257 | 0.040 |
Why?
| | Glycoproteins | 2 | 2015 | 342 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 47 | 0.040 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 294 | 0.040 |
Why?
| | Workload | 1 | 2002 | 167 | 0.040 |
Why?
| | Cholangiography | 1 | 2000 | 17 | 0.040 |
Why?
| | Probability | 1 | 2001 | 304 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 248 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 56 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 178 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1289 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 16 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 431 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 996 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 1024 | 0.040 |
Why?
| | Quality of Health Care | 3 | 2012 | 642 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Body Mass Index | 1 | 2008 | 2389 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 87 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 39 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 142 | 0.040 |
Why?
| | Eating | 2 | 2003 | 380 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 230 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 822 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 50 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 580 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1316 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 76 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 477 | 0.040 |
Why?
| | Montana | 1 | 2018 | 20 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 129 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 28 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 327 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 660 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 61 | 0.040 |
Why?
| | Keratins | 2 | 2010 | 173 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2019 | 236 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 120 | 0.040 |
Why?
| | Cachexia | 1 | 1999 | 71 | 0.040 |
Why?
| | Pedigree | 1 | 2019 | 514 | 0.030 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 341 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 130 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 528 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 56 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 195 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 740 | 0.030 |
Why?
| | Jejunostomy | 1 | 1997 | 13 | 0.030 |
Why?
| | Dinoprostone | 1 | 1998 | 191 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 112 | 0.030 |
Why?
| | Femoral Fractures | 1 | 1998 | 76 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 156 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Candidiasis | 1 | 1997 | 56 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 214 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1502 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 20 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 23 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 39 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 145 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 88 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 167 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 614 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 268 | 0.030 |
Why?
| | Neck | 1 | 2017 | 101 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 213 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 6 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 93 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 21 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 220 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 328 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 430 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 29 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 976 | 0.030 |
Why?
| | Histones | 1 | 2021 | 636 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 452 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 87 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 171 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2224 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 499 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 89 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 14 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1386 | 0.030 |
Why?
| | Virion | 1 | 2015 | 93 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 460 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 166 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 956 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5472 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 136 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 730 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 485 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 89 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 601 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 434 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 25 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 594 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 111 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 984 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 130 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 697 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 812 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 266 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3566 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 269 | 0.030 |
Why?
| | Caspase 1 | 1 | 2014 | 144 | 0.030 |
Why?
| | Phosphorylation | 1 | 1998 | 1759 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 322 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 350 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2837 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.030 |
Why?
| | Autoantigens | 1 | 2016 | 430 | 0.030 |
Why?
| | Hemorrhage | 1 | 1998 | 722 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3284 | 0.020 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 49 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 60 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 83 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2013 | 189 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 52 | 0.020 |
Why?
| | International Agencies | 1 | 2012 | 35 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.020 |
Why?
| | Thoracotomy | 1 | 2012 | 75 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 91 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 219 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1147 | 0.020 |
Why?
| | Homeostasis | 1 | 2016 | 621 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 385 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 307 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 69 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 140 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 67 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 304 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 24 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1118 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 367 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1199 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 195 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 585 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 286 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 786 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 282 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 268 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 384 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 315 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1502 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 21 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 22 | 0.020 |
Why?
| | Risk | 1 | 2013 | 912 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 601 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1266 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1120 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 172 | 0.020 |
Why?
| | Universities | 1 | 2013 | 433 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 19 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 150 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 622 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2804 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1793 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 68 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 435 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 14 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 54 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 136 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2139 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 141 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 143 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 24 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 186 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 893 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 44 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 88 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 898 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2900 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 75 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 94 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 267 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2071 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1570 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 251 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 288 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2167 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 1007 | 0.020 |
Why?
| | Swine | 1 | 2010 | 775 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 515 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 684 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 4 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 224 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 255 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2006 | 25 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4295 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 181 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1062 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 321 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2607 | 0.020 |
Why?
| | Radiotherapy | 1 | 2006 | 201 | 0.010 |
Why?
| | Infant | 1 | 2019 | 9465 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 402 | 0.010 |
Why?
| | Patient Discharge | 1 | 2011 | 897 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2181 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 114 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 60 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 68 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 31 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 82 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4565 | 0.010 |
Why?
| | Work Schedule Tolerance | 1 | 2002 | 49 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 353 | 0.010 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 96 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 28 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 55 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 44 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 269 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 239 | 0.010 |
Why?
| | Continuity of Patient Care | 1 | 2002 | 284 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 64 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 34 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 200 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 54 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2057 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2992 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 522 | 0.010 |
Why?
| | RNA | 1 | 2001 | 921 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1171 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 6763 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1468 | 0.000 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|